GO
Loading...

Johnson & Johnson

More

  • UPDATE 1-U.S. FDA approves Bristol-Myers, J&J HIV pills Thursday, 29 Jan 2015 | 6:35 PM ET

    Jan 29- The U.S. Food and Drug Administration on Thursday approved two fixed-dose HIV pills that combine protease inhibitors- one made by Bristol-Myers Squibb Co and the other by Johnson& Johnson- both with a boosting agent produced by Gilead Sciences Inc.. Bristol-Myers said its drug, Evotaz, is a once-daily pill containing Reyataz, also known as atazanavir, a...

  • Final Glance: Medical Devices companies Thursday, 29 Jan 2015 | 6:14 PM ET

    Allergan rose$. 03 or percent, to $222.39. Baxter International Inc. rose $1.22 or 1.7 percent, to $71.38. Boston Scientific Corp. rose$. 26 or 1.8 percent, to $14.85.

  • Final Glance: Pharmaceuticals companies Thursday, 29 Jan 2015 | 6:14 PM ET

    Baxter International Inc. rose $1.22 or 1.7 percent, to $71.38. Bristol-Myers Squibb Co. fell$. 19 or. 3 percent, to $61.14. Hospira rose$. 13 or. 2 percent, to $64.78.

  • Abbott CEO losing no sleep over stronger dollar Thursday, 29 Jan 2015 | 3:15 PM ET

    Jan 29- Abbott Laboratories' chief executive officer is not worried about the stronger dollar, telling analysts on Thursday his company will better withstand its painful effects than rivals due to its European factories and growing sales of nutritional products, medical diagnostics and medical optics. Half of its sales are in emerging markets, like China and...

  • Midday Glance: Pharmaceuticals companies Thursday, 29 Jan 2015 | 1:23 PM ET

    Baxter International Inc. rose$. 68 or 1.0 percent, to $70.84. Bristol-Myers Squibb Co. fell$. 62 or 1.0 percent, to $60.72. Hospira fell$. 68 or 1.1 percent, to $63.97.

  • Midday Glance: Medical Devices companies Thursday, 29 Jan 2015 | 1:23 PM ET

    Allergan fell $1.30 or. 6 percent, to $221.06. Baxter International Inc. rose$. 68 or 1.0 percent, to $70.84. Boston Scientific Corp. rose$. 04 or. 3 percent, to $14.63.

  • The regulator's decision, which comes in over two months ahead of its review date, represents a fourth indication for the drug, sold by Johnson& Johnson and Pharmacyclics Inc. Although WM occurs only in up to 1,500 patients in the United States each year, the approval highlights the strength of the Imbruvica franchise, Roth Capital Partner's Joseph Pantginis...

  • FDA expands use of Imbruvica to treat rare form of cancer Thursday, 29 Jan 2015 | 11:29 AM ET

    Jan 29- The U.S. Food and Drug Administration said it cleared an expanded use of Imbruvica to treat Waldenström's macroglobulinemia, a rare form of cancer that begins in the body's immune system. The approval represents a fourth indication for the drug, sold by Johnson& Johnson and Pharmacyclics Inc, since its initial approval in November 2013.

  • Jan 29- Thermo Fisher Scientific Inc, the world's largest maker of scientific instruments, forecast 2015 sales and earnings below analysts' expectations, becoming the latest U.S. healthcare company to warn about a strengthening dollar. The company expects profit to be hit by 58 cents in 2015. It forecast $7.22 to $7.40, excluding special items, below analysts'...

  • Early Glance: Pharmaceuticals companies Thursday, 29 Jan 2015 | 10:40 AM ET

    Baxter International Inc. rose$. 57 or. 8 percent, to $70.73. Bristol-Myers Squibb Co. fell$. 77 or 1.3 percent, to $60.56. Hospira fell$. 49 or. 8 percent, to $64.16.

  • Early Glance: Medical Devices companies Thursday, 29 Jan 2015 | 10:40 AM ET

    Allergan fell$. 80 or. 4 percent, to $221.56. Baxter International Inc. rose$. 57 or. 8 percent, to $70.73. St. Jude Medical Inc. fell$. 86 or 1.3 percent, to $66.53.

  • Jan 29- Abbott Laboratories forecast full-year profit largely in line with analysts' estimates even as other large drugmakers have warned of a stronger dollar hurting their results. The company, which received more than 70 percent of revenue from outside the United States, said it expects 2015 earnings of $2.10- $2.20 per share, compared with the average...

  • NEW YORK, Jan 29- When Marty Weinstein decided to quit smoking, he took a friend's advice and tried electronic cigarettes rather than government-approved nicotine replacement products. E-cigarette makers in the United States are barred from explicitly marketing the products as smoking cessation devices, but have found ways to appeal legally to smokers who...

  • Final Glance: Pharmaceuticals companies Wednesday, 28 Jan 2015 | 6:07 PM ET

    Baxter International Inc. fell$. 50 or. 7 percent, to $70.16. Bristol-Myers Squibb Co. fell$. 66 or 1.1 percent, to $61.33. Hospira fell$. 84 or 1.3 percent, to $64.65.

  • Final Glance: Medical Devices companies Wednesday, 28 Jan 2015 | 6:07 PM ET

    Allergan fell $3.39 or 1.5 percent, to $222.36. Baxter International Inc. fell$. 50 or. 7 percent, to $70.16. Boston Scientific Corp. fell$. 15 or 1.0 percent, to $14.59.

  • Midday Glance: Pharmaceuticals companies Wednesday, 28 Jan 2015 | 1:21 PM ET

    Baxter International Inc. rose$. 17 or. 2 percent, to $70.83. Bristol-Myers Squibb Co. rose$. 48 or. 8 percent, to $62.47. Hospira fell$. 21 or. 3 percent, to $65.28.

  • Midday Glance: Medical Devices companies Wednesday, 28 Jan 2015 | 1:21 PM ET

    Allergan fell$. 92 or. 4 percent, to $224.83. Baxter International Inc. rose$. 17 or. 2 percent, to $70.83. Boston Scientific Corp. rose$. 01 or percent, to $14.75.

  • Early Glance: Pharmaceuticals companies Wednesday, 28 Jan 2015 | 10:41 AM ET

    Baxter International Inc. rose$. 27 or. 4 percent, to $70.93. Bristol-Myers Squibb Co. rose$. 66 or 1.1 percent, to $62.65. Hospira rose$. 30 or. 5 percent, to $65.79.

  • Early Glance: Medical Devices companies Wednesday, 28 Jan 2015 | 10:41 AM ET

    Allergan rose$. 09 or percent, to $225.84. Baxter International Inc. rose$. 27 or. 4 percent, to $70.93. Boston Scientific Corp. rose$. 09 or. 6 percent, to $14.83.

  • Final Glance: Medical Devices companies Tuesday, 27 Jan 2015 | 6:08 PM ET

    Allergan fell $2.08 or. 9 percent, to $225.75. Baxter International Inc. fell$. 22 or. 3 percent, to $70.66. Boston Scientific Corp. fell$. 22 or 1.5 percent, to $14.74.